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It is known that individuals with Down syndrome develop Alzheimer’s disease with an early age at onset,
although associated genetic risk factors have not been widely studied. We tested whether genes that
increase the risk of late-onset Alzheimer’s disease inﬂuence the age at onset in Down syndrome using
genome-wide association data for age at onset of dementia in a small sample of individuals (N ¼ 67) with
Down syndrome. We tested for association with loci previously associated with Alzheimer’s disease risk
and, despite the small size of the study, we detected associations with age at onset of Alzheimer’s disease
in Down syndrome with PICALM (b ¼ 3.31, p ¼ 0.011) and the APOE loci (b ¼ 3.58, p ¼ 0.014). As dementia
in people with Down syndrome is relatively understudied, we make all of these data publicly available to
encourage further analyses of the problem of Alzheimer’s disease in Down syndrome.
 2013 Elsevier Inc. Open access under CC BY license.1. Introduction
Down syndrome (DS), also referred to as trisomy 21, is caused by
an extra copy of chromosome 21. Occurring in approximately 1 in
800 live births, it is the most common chromosomal abnormality
resulting in learning difﬁculties.
The prevalence of Alzheimer’s disease (AD) in people with DS
increases signiﬁcantly with age, and dementia in people with DS is
one of the most common forms of dementia among individuals
under the age of 50 years. Despite the occurrence of AD pathology,
including amyloid plaques and neuroﬁbrillary tangles, in the brains
of individuals with DS as young as 40 years (Wisniewski et al.,
1994), the age at onset (AAO) of AD can vary widely. The mean
AAO of dementia is 50 to 55 years (Prasher and Krishnan, 1993),
with a range from 38 to 70 years.
The early-onset AD that occurs in people with DS is thought to
be largely due to the triplication of APP, which is located on chro-
mosome 21. Indeed, APP duplications have been shown to cause
early-onset AD in the disomic population (McNaughton et al., 2012;ge-Related Diseases, King’s
K. Tel.: þ44 207 848 6171;
).
 license.Rovelet-Lecrux et al., 2006; Sleegers et al., 2006), although these are
not always fully penetrant (Hooli et al., 2012).
As dementia in the DS population can develop over a range of
ages, it is likely that, as with sporadic AD in the general population,
genetic factors play a major role. Although mutations in a small
number of genes associated with the production of amyloid, such
as APP, PSEN1, and PSEN2, have been found to cause early-onset AD
in the general population, the majority of AD cases are sporadic
and are likely to have a complex genetic etiology. APOE is a key
genetic risk factor for late-onset AD in the general population
(Corder et al., 1993), and large genome-wide association studies
(GWAS) carried out in recent years have identiﬁed further risk
genes: CLU, PICALM, BIN1, CR1, ABCA7, CD2AP, EPHA1, CD33, and the
MS4 locus (Harold et al., 2009; Hollingworth et al., 2011; Naj et al.,
2011; Seshadri et al., 2010). Although we and others have shown
APOE to affect AD risk in DS individuals (Deb et al., 2000; Prasher
et al., 2008; Royston et al., 1996), this result has not been repli-
cated in all studies (Margallo-Lana et al., 2004; van Gool et al.,
1995).
A study by Patel et al. (2011) examined SNPs in 28 genes asso-
ciated with AD risk, selected from literature published up until
March 2008. Five genes including APOE were associated with AD
risk.
No therapies have speciﬁcally been developed for the treatment
of AD in DS, and, as the life expectancy of people with DS is
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affecting age-related diseases in this population (Coppus et al.,
2006; Holland et al., 2000).
Given the almost universal presence of early-onset AD
pathology in people with DS, factors affecting AAO, severity, and
disease progression need closer analysis. This may also provide
information relevant to those at risk of developing AD in the general
population. In this study, we examined the impact of SNPs that have
recently been associatedwith AD risk in the general population, in 2
large meta-analyses (Hollingworth et al., 2011; Naj et al., 2011),
upon AAO of AD in people with DS.2. Methods
2.1. Samples
A total of 158 DNA samples were prepared from blood or
brain from individuals with DS using a commercially available
kit (DNeasy Blood and Tissue kit, Qiagen). Ninety-four blood
samples were collected from two clinical trials (MEADOWS (Hanney
et al., 2012), DOWNSLIT [http://public.ukcrn.org.uk/search/StudyDetail.
aspx?StudyID¼5927]), and 64 brain samples from the Newcastle and
London Neurodegenerative Disease brain banks, and Thomas Willis
Oxford Brain Collection, as part of the Brains for Dementia Research
initiative, the Medical Research Council Alzheimer Brain & Tissue Bank
in Edinburgh, the NICHD Brain and Tissue Bank for Developmental
Disorders, University of Maryland (NICHD Contract No. N01-HD-4-
3368 and NO1-HD-4-3383), the Alzheimer’s Disease Research Center,
Washington University in St. Louis, and the Netherlands Brain Bank. All
samples were anonymous to the researchers carrying out the geno-
typing and genotyping analysis. Samples were requested and collected
with permission from North West, and Newcastle and North Tyneside
Research Ethics Committees. Samples were collected with informed
consent using processes approved for each brain bank or by the
Research Ethics Committees.
The MEADOWS trial examined the use of memantine as
a treatment for cognitive decline in DS over the course of 52 weeks.
Similarly, the DOWNSLIT trial used lithium to improve cognitive
function in DS over the course of 8 weeks. The use of memantine in
the MEADOWS trial did not alter the risk of developing dementia or
AAO (c2¼ 0.031, p¼ 0.861 and t¼ 0.291, p¼ 0.745 respectively). No
individuals in the DOWNSLIT trial had a diagnosis of or developed
dementia. Cohort demographics are shown in Table 1. There were
no differences in gender frequencies between the blood and brain
samples cohorts (c2 ¼ 0.013, p ¼ 0.908). Individuals in the autopsy
cohort were older than those in the clinical cohort (ManneWhitney
U test, p ¼ 0.008).
For samples from the clinical trials, AAO of dementia was
recorded by the trial psychiatrist (M.H.) and the youngest AAO was
34 years. The mean duration of dementia before death in people
with DS is approximately 5 years (Prasher and Krishnan, 1993;
Prasher et al., 2008). For the autopsy cohort, diagnosis of dementia
and AAO had not been routinely collected. Therefore we deﬁned
AAO as age of death minus 5 years for all individuals over the age ofTable 1
Age and gender of clinical and autopsy cohorts for all samples, and for the 67
samples used in the age at onset (AAO) analysis
Cohort Age, y (mean  SD) Gender (% male)
Clinical 46.61 (10.63) 55.3
Autopsy 49.03 (16.95) 56.3
Clinical (AAO) 54.18 (5.45) 52.9
Autopsy (AAO) 55.72 (7.97) 52.034. This, of course, assumes that all individuals over this age had
dementia.
2.2. Genotyping and quality control
DNA was genotyped in the UCL Genomics Centre using
HumanOmniExpress-12v1_H beadchips. The data were assembled
in Genome Studio (Illumina, San Diego, CA). A total of 158 samples
were genotyped. After the initial quality control check, 129 samples
(72 male and 57 female) and 642,251 SNPs remained.
SNPs were ﬁrst curated in Genome Studio. Those SNPs in Chr 1
to 22 that failed the call frequency parameter (deﬁned as <0.98)
were analyzed by re-cluster in Genome Studio. Within this group,
only those SNPS that passed quality parameters were kept (namely
Het excess between 0.1 and 0.1 and cluster separation >0.3). All
others were discarded (zeroed in Genome Studio). Samples with
call rates <0.975 after this process were excluded (9 samples and
29,537 SNPs were excluded in this step).
Samples were curated in PLINK (Purcell et al., 2007) for gender
check and relatedness (deﬁned as PiHat >0.125), and SNPs were
checked for minor allele frequency (0.01), haplotype missingness
(p < 10e-4), and HardyeWeinburg Equilibrium (p < 10e-6). Ten
samples were excluded (6 were duplicates of another sample in the
study). 58,737 SNPs were excluded at this stage, of which 58,405
were due to MAF<0.01. The outcome of this process resulted in 139
samples (61 female and 78 male) and 642,251 SNPs for further
analysis.
Samples were merged with Hapmap data. MultiDimensional
Scaling on the combined samples was used for assessing population
outliers. Those samples that were 4 standard deviations away from
the mean of CEU/TSI combined data were excluded. Ten samples
were found to be nonwhite or mixed. At this stage, only 129
samples (72 male and 57 female) and 642,251 SNPs remained.
As dementia develops at a mean age of 50 to 55 years, and in our
clinical sample series, the earliest age of dementia onset was
34 years, we excluded all cases with age <34 at their last cognitive
assessment or autopsy. This resulted in 120 valid samples with 70
having dementia (clinically deﬁned, or belonging to the autopsy
cohort). Among the 70 dementia cases, 3 had no AAO in the record.
The analysis was based on 67 cases (Table 1). The youngest age in
the autopsy series was 39, and therefore AAO in this case was 34 as
deﬁned above. There were no differences in gender frequencies
between the clinical and autopsy samples used at this stage (c2 ¼
0.005, p ¼ 0.946) or age (ManneWhitney U test, p ¼ 0.419).
The MEADOWS trial showed that memantine was not an effec-
tive treatment for cognitive decline in DS (Hanney et al., 2012).
There were no AAO differences between those taking placebo and
memantine in the 17 samples used for the AAO analysis (t¼0.621,
p ¼ 0.545). No individuals from the DOWNSLIT trial developed
dementia, and so were excluded from this further analysis.
Analysis was carried out in PLINK using a linear regression with
AAO and the SNPs in an additivemodel. The SNPswere selected from
previous GWAS meta-analyses (Hollingworth et al., 2011; Naj et al.,
2011) and had reached statistical signiﬁcance or possible signiﬁ-
cance (Supplementary Table 8 (Hollingworth et al., 2011), Tables 1
and 2, and Supplementary Table 5 (Naj et al., 2011)). Of the 531 SNPs
found in these 2 papers, only 157 SNPs were also successfully gen-
otyped by HumanOmniExpress-12v1_H in this study (most were
absent in this array). A detailed list can be found in Table S1. Among
these, 35 SNPs from 15 genes were around the APOE region.
Component 1 and component 2 in PLINK MultiDimensional
Scaling were used as covariates, in addition to gender and the
classiﬁcation of the sample as clinical or autopsy. A nominal p value
of 0.05 was used as a cut-off for further analysis.
R was used for graph plotting (R Development Core Team, 2008).
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We generated a composite score of AD risk allele loading based
on the SNPs reported by Bettens et al. (2013). We correlated the age
of onset in our DS cases with the composite score derived from AD
studies. In addition, we compared AAO between the quintiles with
highest and lowest score. For details, please refer to the
Supplementary Method (MethodS1).3. Results
We found a signiﬁcant association between AAO and variation at
the chromosome 11 PICALM region. Three SNPS, rs2888903 (b ¼
3.31, p ¼ 0.011), rs7941541 (b ¼ 3.92, p ¼ 0.016), and rs10751134
(b ¼ 2.78, p ¼ 0.040) were associated (Fig. 1AeC). All of these
PICALM SNPs show a decreased AAO in individuals who are
homozygous for the major allele.
There is also a signiﬁcant association between AAO and APOE,
replicating associations found with AD risk in previous studies. The
median AAO in patients homozygous for the minor allele in
rs405509, a SNP linked with APOE, was 5 years older than those
homozygous for the major allele (b¼ 3.58, p¼ 0.014), (Fig. 1D). Two
SNPS in TOMM40, which is immediately 50 to APOE, were also
associated with AAO; rs2075650 (b ¼ 3.4, p ¼ 0.036, Fig. 1E) andFig. 1. Median age of onset of dementia according to genotype. 0 ¼ homozygous major allel
(A/G). C ¼ rs10751134 (A/G). D ¼ rs405509 (C/T). E ¼ rs2075650 (A/G). F ¼ rs8106922 (A/Grs8106922 (b ¼ 3.32, p ¼ 0.031, Fig. 1F). These PICALM, APOE and
TOMM40 SNPs show the same direction of effect as in studies in the
general population: that is, an increased risk of AD in the general
population equates with an earlier AAO in the DS population in this
study.
The only SNP in our study that showed a signiﬁcant effect in the
direction opposite to that found in the general population was
rs3865444 in CD33; but it is not protective, as was found in the AD
GWAS studies (Table S3). The other genes previously found to have
been associated with AD risk did not have signiﬁcant associations
with AAO of AD (Table S3).
With regard to risk score analysis, when comparing the upper
and lower quintiles, AAO changed from 48.1 (SD 6.3) to 52.9 (SD
6.9) (Table S4) (ManneWhitney U test, p ¼ 0.084). There is a trend
toward an association between AAO and allele composite score (p¼
0.166) (Figure S1). For every increase of 1 in the composite score,
AAO decreased by 0.67 year. All tests for the composite score were
insigniﬁcant if APOE SNP rs405509 is excluded.4. Discussion
Themajor alleles of the 3 SNPS in PICALM, rs2888903, rs7941541,
and rs10751134, are associated with an increased risk of AD in the
general population and an earlier AAO in the DS population.e, 1 ¼ heterozygote, 2 ¼ homozygous minor allele. A ¼ rs2888903 (T/G). B ¼ rs7941541
).
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the most signiﬁcant in the study by Naj et al. (2011) was not
signiﬁcantly associated with AAO of AD in our cohort (data not
shown), but had the same protective result as that found by Naj
et al. (2011). The 3 PICALM SNPs noted in this study are in linkage
disequilibrium (LD). A further PICALM SNP that has been associated
with AD in the general population, rs3851179, is in LD with both
rs7941541 and rs10751134. As with rs561655, we do not ﬁnd this
SNP to be signiﬁcantly associated in our study, but its effect is
protective, as found in the general population.
Similarly, the results for the APOE SNP rs405509 and TOMM40 SNP
rs8106922 are in accordance with the study by Naj et al. (2011), with
theminor allele having a protective effect upon the onset of dementia.
The minor allele of rs2075650 in TOMM40 is associated with
increased risk of AD (Naj et al., 2011) and an earlier AAO in our current
study, although this is most likely due to LD with the APOE locus.
With regard to the composite risk score analysis, the level of
signiﬁcance is likely limited by our sample size; but this analysis
has shown that using a composite score may help in predicting the
risk and should be one of the directions in future studies.
The score is likely dominated by APOE, given that the other SNPs
have a much lower OR in the AD meta-analyses.
This GWAS was powered to detect only the risk associated with
APOE, and is too underpowered to detect the many more subtle
changes associated with AD risk in the general population.
Although APOE has previously been associated with the risk of
developing AD in individuals with DS, PICALM has not. This study
therefore highlights the value of carrying out GWAS in the DS
population. Even with a small sample size, we are examining
a population with a more homogeneous AD risk than that of the
general population, and by using the results of previous GWAS to
focus our study, we can detect genetic risk factors that have not yet
been associated with DS.
Any differences between our results and those of AD GWAS
meta-analyses (e.g., Hollingworth et al., 2011; Naj et al., 2011) are
most likely due to the much lower number of samples used in our
study. Because of this small sample size, we have not currently
applied a multiple testing correction to our data, which we
acknowledge to be a limitation of this study. AD in DS is still
a relatively understudied area in the ﬁeld of neurodegeneration,
and this study highlights the need for larger collaborative studies
that would improve our chances of dissecting the key genetic
pathways which accelerate the onset of dementia. As studies in this
ﬁeld continue, we can identify further similar genetic risk factors
between AD in the general population and DS. These similarities
can guide us towards therapies which may beneﬁt both
populations.
Given the high occurrence of AD in people with DS, we have the
opportunity to examine factors that affect AAO and disease
progression, but only when large international collaborations are in
place will we be able to fully take advantage of this opportunity. For
this reason, we have made all of the genome-wide data available as
PLINK ﬁles (Data S1), which we hope other researchers in this area
will make use of in meta-analysis studies.
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